相似文献
1
Enhancement of endocannabinoid signaling and the pharmacotherapy of depression.
Pharmacol Res. 2007 Nov;56(5):360-6. doi: 10.1016/j.phrs.2007.09.003. Epub 2007 Sep 11.
2
Role of endocannabinoid signaling in anxiety and depression.
Curr Top Behav Neurosci. 2009;1:347-71. doi: 10.1007/978-3-540-88955-7_14.
3
Characterization of the endocannabinoid system, CB(1) receptor signalling and desensitization in human myometrium.
Br J Pharmacol. 2011 Nov;164(5):1479-94. doi: 10.1111/j.1476-5381.2011.01425.x.
4
Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.
J Neurochem. 2008 Sep;106(6):2322-36. doi: 10.1111/j.1471-4159.2008.05567.x. Epub 2008 Jul 15.
5
[Pharmacological exploitation of the endocannabinoid system: new perspectives for the treatment of depression and anxiety disorders?].
Braz J Psychiatry. 2010 May;32 Suppl 1:S7-14.
6
The endocannabinoid system in Huntington's disease.
Curr Pharm Des. 2008;14(23):2317-25. doi: 10.2174/138161208785740108.
7
The role of the CB1 cannabinoid receptor and its endogenous ligands, anandamide and 2-arachidonoylglycerol, in amphetamine-induced behavioural sensitization.
Behav Brain Res. 2008 Mar 5;187(2):289-96. doi: 10.1016/j.bbr.2007.09.022. Epub 2007 Sep 25.
8
The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism.
Mini Rev Med Chem. 2007 Aug;7(8):769-79. doi: 10.2174/138955707781387920.
9
Endocannabinoids in the treatment of mood disorders: evidence from animal models.
Curr Pharm Des. 2009;15(14):1623-46. doi: 10.2174/138161209788168029.
10
Chronic, noninvasive glucocorticoid administration suppresses limbic endocannabinoid signaling in mice.
Neuroscience. 2012 Mar 1;204:83-9. doi: 10.1016/j.neuroscience.2011.08.048. Epub 2011 Sep 10.
引用本文的文献
1
Circuit mechanisms governing endocannabinoid modulation of affective behaviour and stress adaptation.
Nat Rev Neurosci. 2025 Sep 11. doi: 10.1038/s41583-025-00961-y.
2
The endocannabinoid system is involved in the anxiety-like behavior induced by dual-frequency 2.65/0.8 GHz electromagnetic radiation in mice.
Front Mol Neurosci. 2024 Apr 15;17:1366855. doi: 10.3389/fnmol.2024.1366855. eCollection 2024.
3
The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer's Disease.
Biomolecules. 2023 Sep 26;13(10):1446. doi: 10.3390/biom13101446.
4
Serum metabonomics as a diagnostic approach for cancer-related fatigue.
Exp Ther Med. 2022 Apr;23(4):256. doi: 10.3892/etm.2022.11181. Epub 2022 Feb 2.
5
Exo- and Endo-cannabinoids in Depressive and Suicidal Behaviors.
Front Psychiatry. 2021 Apr 23;12:636228. doi: 10.3389/fpsyt.2021.636228. eCollection 2021.
6
Do Adolescent Exposure to Cannabinoids and Early Adverse Experience Interact to Increase the Risk of Psychiatric Disorders: Evidence from Rodent Models.
Int J Mol Sci. 2021 Jan 13;22(2):730. doi: 10.3390/ijms22020730.
7
Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling.
EMBO Mol Med. 2020 Nov 6;12(11):e11776. doi: 10.15252/emmm.201911776. Epub 2020 Oct 5.
8
Endocannabinoid System Components as Potential Biomarkers in Psychiatry.
Front Psychiatry. 2020 Apr 27;11:315. doi: 10.3389/fpsyt.2020.00315. eCollection 2020.
9
Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.
Pharmaceuticals (Basel). 2010 Aug 17;3(8):2689-2708. doi: 10.3390/ph3082689.
10
Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.
Pharmaceuticals (Basel). 2010 Aug 10;3(8):2517-2553. doi: 10.3390/ph3082517.
本文引用的文献
1
Antidepressant-like activity of the fatty acid amide hydrolase inhibitor URB597 in a rat model of chronic mild stress.
Biol Psychiatry. 2007 Nov 15;62(10):1103-10. doi: 10.1016/j.biopsych.2006.12.001. Epub 2007 May 23.
2
Estrogen recruits the endocannabinoid system to modulate emotionality.
Psychoneuroendocrinology. 2007 May;32(4):350-7. doi: 10.1016/j.psyneuen.2007.02.003. Epub 2007 Mar 27.
3
Identification of a novel endocannabinoid-hydrolyzing enzyme expressed by microglial cells.
J Neurosci. 2007 Mar 14;27(11):2883-9. doi: 10.1523/JNEUROSCI.4830-06.2007.
4
Evaluation of fatty acid amide hydrolase inhibition in murine models of emotionality.
Psychopharmacology (Berl). 2007 May;192(1):61-70. doi: 10.1007/s00213-006-0689-4. Epub 2007 Feb 6.
5
Involvement of cannabinoid CB2 receptor in alcohol preference in mice and alcoholism in humans.
Pharmacogenomics J. 2007 Dec;7(6):380-5. doi: 10.1038/sj.tpj.6500431. Epub 2006 Dec 26.
6
Discovery and characterization of a Ca2+-independent phosphatidylethanolamine N-acyltransferase generating the anandamide precursor and its congeners.
J Biol Chem. 2007 Feb 9;282(6):3614-23. doi: 10.1074/jbc.M606369200. Epub 2006 Dec 7.
7
Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain.
Ann N Y Acad Sci. 2006 Aug;1074:514-36. doi: 10.1196/annals.1369.052.
8
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
Lancet. 2006 Nov 11;368(9548):1660-72. doi: 10.1016/S0140-6736(06)69571-8.
9
A biosynthetic pathway for anandamide.
Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13345-50. doi: 10.1073/pnas.0601832103. Epub 2006 Aug 28.
10
The fatty-acid amide hydrolase inhibitor URB597 does not affect triacylglycerol hydrolysis in rat tissues.
Pharmacol Res. 2006 Nov;54(5):341-4. doi: 10.1016/j.phrs.2006.06.008. Epub 2006 Jun 29.
Zotero 插件